Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Marilyn J. Telen, Ted Wun, Timothy L. McCavit, Laura M. De Castro, Lakshmanan Krishnamurti, Sophie Lanzkron, Lewis L. Hsu, Wally R. Smith, Seungshin Rhee, John L. Magnani, Helen Thackray

Blood (2015) 125 (17): 2656–2664.

https://doi.org/10.1182/blood-2014-06-583351

Published: 2015

Includes: Supplemental data

Journal Articles

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

Ted Wun, MD, Marilyn J. Telen, MD, Lakshmanan Krishnamurti, MD, Timothy L. McCavit, MD, Laura M DeCastro, MD, Henry Flanner, ME, Frans A. Kuypers, PhD, Sandra K. Larkin, MS, Seungshin Rhee, MS, John L. Magnani, PhD, Helen M. Thackray, MD

Blood (2014) 124 (21): 2704.

https://doi.org/10.1182/blood.V124.21.2704.2704

Published: 2014

Journal Articles

An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia

Timothy L. McCavit, MD, MS, Lakshmanan Krishnamurti, MD, Lewis L. Hsu, MD, PhD, Charles T. Quinn, MD, MS, Isaac Odame, MD, Ofelia A. Alvarez, MD, Catherine Driscoll, MD, Kim Smith-Whitley, MD, Seungshin Rhee, MS, Ted Wun, MD, Marilyn J. Telen, MD, Helen Thackray, MD

Blood (2013) 122 (21): 2206.

https://doi.org/10.1182/blood.V122.21.2206.2206

Published: 2013

Journal Articles

Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease

Laura M. De Castro, MD, Ted Wun, MD, Sophie Lanzkron, MD MHS, Wally R. Smith, MD, Kathryn L. Hassell, MD, Abdullah Kutlar, MD, Kim Smith-Whitley, MD, Seungshin Rhee, MS, Marilyn J. Telen, MD, Helen Thackray, MD

Blood (2013) 122 (21): 775.

https://doi.org/10.1182/blood.V122.21.775.775

Published: 2013

Journal Articles

GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease

Marilyn J. Telen, MD, Ted Wun, MD, Timothy L. McCavit, MD, MS, Laura M. De Castro, MD, Lakshmanan Krishnamurti, MD, Sophie Lanzkron, MD, MHS, Lewis L. Hsu, MD, PhD, Wally R. Smith, MD, Seungshin Rhee, MS, John L. Magnani, PhD, Helen Thackray, MD

Blood (2013) 122 (21): 776.

https://doi.org/10.1182/blood.V122.21.776.776

Published: 2013

Journal Articles

A Pilot Study of Tapered Oral Dexamethasone for the Acute Chest Syndrome of Sickle Cell Disease.

Charles T. Quinn, MD, MS, Marie J. Stuart, MD, Karen Kesler, PhD, Kenneth I. Ataga, MD, Winfred C. Wang, MD, Lori Styles, MD, Kim Smith-Whitley, MD, Ted Wun, MD, Suba Krishnan, MD, Frans A. Kuypers, PhD, Yamaja Setty, PhD, Nigel S. Key, MB, ChB, Seungshin Rhee, MS, George R. Buchanan, MD

Blood (2009) 114 (22): 1515.

https://doi.org/10.1182/blood.V114.22.1515.1515

Published: 2009

NARROW

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia

Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease

GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease

A Pilot Study of Tapered Oral Dexamethasone for the Acute Chest Syndrome of Sickle Cell Disease.

Email alerts

ASH Publications

American Society of Hematology

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia

Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease

GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease

A Pilot Study of Tapered Oral Dexamethasone for the Acute Chest Syndrome of Sickle Cell Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only